**Prognostic markers for urologic cancers**

Jay D. Raman, MD

Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

Referring to the article published on pp. 8151-8154 in this issue


Improved prediction of disease related oncologic outcomes is essential for improved patient counseling prior to surgery. The concept of chronic inflammatory states and association with cancer recurrence and survival is a growing area of interest. Indeed a number of studies highlight the potential prognostic benefit across different malignancies.

Nonetheless, the impact of neutrophil:lymphocyte ratio (NLR) is variable and certainly not uniform. As highlighted by Bazzi et al (as well as others), NLR had no significant prognostic benefit for recurrence-free and cancer-specific survival for clear cell renal cell carcinoma (ccRCC).1 One wonders if some of these observations are a function of a heterogenous cohort of ccRCC cases ranging from T1a to T4 tumors of various Fuhrman grades. Indeed, a focus on more biologically aggressive ccRCC at higher risk of recurrence and mortality may demonstrate a greater degree of association.

Furthermore, whilst these authors noted an association of NLR with overall survival, there was no incremental benefit over a base model constructed from clinical measures of frailty. These observations highlight that accurate pre-surgical notation of baseline clinical morbidities may be invaluable when assessing overall prognosis for urologic oncology patients. In that regard, more refined scales such as ECOG performance status, Charlson-Romano index, or an amalgam to create a Frailty Index Score may be superior to the ASA score alone.2,3

---

**References**

